Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash-to-Debt No Debt
CBIO's Cash-to-Debt is ranked lower than
62% of the 1056 Companies
in the Global Biotechnology industry.

( Industry Median: 73.06 vs. CBIO: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
CBIO' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.66  Med: 38.46 Max: No Debt
Current: No Debt
0.66
No Debt
Equity-to-Asset 0.98
CBIO's Equity-to-Asset is ranked higher than
65% of the 770 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. CBIO: 0.98 )
Ranked among companies with meaningful Equity-to-Asset only.
CBIO' s Equity-to-Asset Range Over the Past 10 Years
Min: -36.68  Med: 0.61 Max: 0.98
Current: 0.98
-36.68
0.98
Debt-to-EBITDA -0.21
CBIO's Debt-to-EBITDA is ranked lower than
99.99% of the 213 Companies
in the Global Biotechnology industry.

( Industry Median: 1.97 vs. CBIO: -0.21 )
Ranked among companies with meaningful Debt-to-EBITDA only.
CBIO' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -2.63  Med: -0.22 Max: 0.19
Current: -0.21
-2.63
0.19
Interest Coverage No Debt
CBIO's Interest Coverage is ranked lower than
99.99% of the 521 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. CBIO: No Debt )
Ranked among companies with meaningful Interest Coverage only.
CBIO' s Interest Coverage Range Over the Past 10 Years
Min: 85.72  Med: No Debt Max: No Debt
Current: No Debt
85.72
No Debt
Piotroski F-Score: 4
Altman Z-Score: 65.43
Beneish M-Score: -3.08
WACC vs ROIC
18.21%
-569.76%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating Margin % -3231.08
CBIO's Operating Margin % is ranked lower than
83% of the 800 Companies
in the Global Biotechnology industry.

( Industry Median: -98.02 vs. CBIO: -3231.08 )
Ranked among companies with meaningful Operating Margin % only.
CBIO' s Operating Margin % Range Over the Past 10 Years
Min: -5117.29  Med: -287.54 Max: 15.3
Current: -3231.08
-5117.29
15.3
Net Margin % -2983.40
CBIO's Net Margin % is ranked lower than
83% of the 800 Companies
in the Global Biotechnology industry.

( Industry Median: -88.19 vs. CBIO: -2983.40 )
Ranked among companies with meaningful Net Margin % only.
CBIO' s Net Margin % Range Over the Past 10 Years
Min: -4246.87  Med: -260.99 Max: 12.72
Current: -2983.4
-4246.87
12.72
ROE % -54.42
CBIO's ROE % is ranked lower than
78% of the 969 Companies
in the Global Biotechnology industry.

( Industry Median: -40.23 vs. CBIO: -54.42 )
Ranked among companies with meaningful ROE % only.
CBIO' s ROE % Range Over the Past 10 Years
Min: -108.92  Med: -47.1 Max: 13.55
Current: -54.42
-108.92
13.55
ROA % -38.94
CBIO's ROA % is ranked lower than
68% of the 1062 Companies
in the Global Biotechnology industry.

( Industry Median: -32.55 vs. CBIO: -38.94 )
Ranked among companies with meaningful ROA % only.
CBIO' s ROA % Range Over the Past 10 Years
Min: -55.57  Med: -13.88 Max: 3.74
Current: -38.94
-55.57
3.74
ROC (Joel Greenblatt) % -550.70
CBIO's ROC (Joel Greenblatt) % is ranked higher than
56% of the 1021 Companies
in the Global Biotechnology industry.

( Industry Median: -430.94 vs. CBIO: -550.70 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
CBIO' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -1169.45  Med: -308.1 Max: 268.6
Current: -550.7
-1169.45
268.6
3-Year Revenue Growth Rate -84.00
CBIO's 3-Year Revenue Growth Rate is ranked lower than
90% of the 604 Companies
in the Global Biotechnology industry.

( Industry Median: 4.00 vs. CBIO: -84.00 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
CBIO' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: -56.95 Max: 69.3
Current: -84
0
69.3
3-Year EBITDA Growth Rate 71.50
CBIO's 3-Year EBITDA Growth Rate is ranked higher than
95% of the 722 Companies
in the Global Biotechnology industry.

( Industry Median: 3.10 vs. CBIO: 71.50 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
CBIO' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: -91.4 Max: 81
Current: 71.5
0
81
3-Year EPS without NRI Growth Rate 69.80
CBIO's 3-Year EPS without NRI Growth Rate is ranked higher than
94% of the 704 Companies
in the Global Biotechnology industry.

( Industry Median: 4.20 vs. CBIO: 69.80 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
CBIO' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: 2.4 Max: 92.9
Current: 69.8
0
92.9
GuruFocus has detected 3 Warning Signs with Catalyst Biosciences Inc CBIO.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» CBIO's 30-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2017

CBIO Guru Trades in Q2 2017

Paul Tudor Jones 14,489 sh (New)
Jim Simons 339,673 sh (+416.43%)
» More
Q3 2017

CBIO Guru Trades in Q3 2017

Paul Tudor Jones Sold Out
Jim Simons 333,773 sh (-1.74%)
» More
Q4 2017

CBIO Guru Trades in Q4 2017

Jim Simons 355,373 sh (+6.47%)
» More
Q1 2018

CBIO Guru Trades in Q1 2018

George Soros 363,070 sh (New)
Jim Simons 556,373 sh (+56.56%)
» More
» Details

Insider Trades

Latest Guru Trades with CBIO

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
George Soros 2018-03-31 New Buy0.17%$14.18 - $35.6 $ 23.64-5%363,070
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:WAR:MAB, SHSE:600556, XKRX:168330, NAS:PIRS, HKSE:08158, NAS:MRUS, NAS:COOL, NAS:PRTK, XPAR:COX, NAS:SBBP, XKRX:200670, NAS:ABUS, XKRX:001630, NAS:CBMG, NAS:CORI, LSE:FARN, NYSE:KDMN, XBRU:CYAD, XKRX:142760, NAS:NK » details
Traded in other countries:HGF2.Germany,
Headquarter Location:USA
Catalyst Biosciences Inc is a clinical-stage biopharmaceutical company. The Company is engaged in creating and developing novel medicines to address serious medical conditions.

Catalyst Biosciences Inc is a clinical-stage biopharmaceutical company. It mainly focuses on developing novel medicines to address serious medical conditions for individuals in need of treatment options. The company emphasizes on product development efforts in the field of hemostasis and to develop valuable therapies for individuals with hemophilia. It is engaged in clinical development of improved, next-generation subcutaneous prophylaxis using enhanced potency Factor VIIa and Factor IX variants.

Top Ranked Articles about Catalyst Biosciences Inc

New Research Coverage Highlights BlackRock Capital Investment, Tootsie Roll Industries, Catalyst Biosciences, Macerich, Quotient Technology, and PennyMac Mortgage Investment Trust — Consolidated Revenues, Company Growth, and Expectations for 2018
Catalyst Biosciences Announces Oral Presentation at the World Federation of Hemophilia 2018 World Congress
Catalyst Biosciences to Host Key Opinion Leader Meeting on Novel Treatments for Hemophilia B and Hemophilia with Inhibitors
Catalyst Biosciences Reports First Quarter Operating & Financial Results and Provides Corporate Update
Catalyst Biosciences Announces Presentation at the 2018 Association for Research in Vision and Ophthalmology Annual Meeting
Catalyst Biosciences Announces Korean Ministry of Food and Drug Safety Approves Addition of Sixth Cohort to the Phase 1/2 Trial of CB 2679d/ISU304 in Individuals with Hemophilia B
Analysis: Positioning to Benefit within Catalyst Biosciences, CorEnergy Infrastructure Trust, PennyMac Mortgage Investment Trust, Raven Industries, Acacia Communications, and Sandy Spring — Research Highlights Growth, Revenue, and Consolidated Results
Catalyst Biosciences Receives $1.5 Million In Two Milestone Payments for Neuronal Nicotinic Receptor (NNR) Asset
Catalyst Biosciences Announces Closing of Public Offering of Common Stock
Catalyst Biosciences Announces Closing of Public Offering of Common Stock

Ratios

vs
industry
vs
history
PB Ratio 2.00
CBIO's PB Ratio is ranked higher than
52% of the 954 Companies
in the Global Biotechnology industry.

( Industry Median: 4.51 vs. CBIO: 2.00 )
Ranked among companies with meaningful PB Ratio only.
CBIO' s PB Ratio Range Over the Past 10 Years
Min: 0.3  Med: 1.2 Max: 12.53
Current: 2
0.3
12.53
PS Ratio 135.89
CBIO's PS Ratio is ranked lower than
76% of the 733 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. CBIO: 135.89 )
Ranked among companies with meaningful PS Ratio only.
CBIO' s PS Ratio Range Over the Past 10 Years
Min: 0.49  Med: 9.37 Max: 347.06
Current: 135.89
0.49
347.06
EV-to-EBIT -5.74
CBIO's EV-to-EBIT is ranked lower than
99.99% of the 262 Companies
in the Global Biotechnology industry.

( Industry Median: 24.43 vs. CBIO: -5.74 )
Ranked among companies with meaningful EV-to-EBIT only.
CBIO' s EV-to-EBIT Range Over the Past 10 Years
Min: -1557.8  Med: -1.9 Max: 43.3
Current: -5.74
-1557.8
43.3
EV-to-EBITDA -5.77
CBIO's EV-to-EBITDA is ranked lower than
99.99% of the 287 Companies
in the Global Biotechnology industry.

( Industry Median: 21.70 vs. CBIO: -5.77 )
Ranked among companies with meaningful EV-to-EBITDA only.
CBIO' s EV-to-EBITDA Range Over the Past 10 Years
Min: -58.7  Med: -1.9 Max: 204.9
Current: -5.77
-58.7
204.9
EV-to-Revenue 184.05
CBIO's EV-to-Revenue is ranked lower than
87% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: 13.46 vs. CBIO: 184.05 )
Ranked among companies with meaningful EV-to-Revenue only.
CBIO' s EV-to-Revenue Range Over the Past 10 Years
Min: -51.2  Med: 6 Max: 180.1
Current: 184.05
-51.2
180.1
Current Ratio 50.15
CBIO's Current Ratio is ranked lower than
55% of the 1035 Companies
in the Global Biotechnology industry.

( Industry Median: 4.21 vs. CBIO: 50.15 )
Ranked among companies with meaningful Current Ratio only.
CBIO' s Current Ratio Range Over the Past 10 Years
Min: 0.89  Med: 6.08 Max: 60.98
Current: 50.15
0.89
60.98
Quick Ratio 50.15
CBIO's Quick Ratio is ranked lower than
52% of the 1035 Companies
in the Global Biotechnology industry.

( Industry Median: 3.92 vs. CBIO: 50.15 )
Ranked among companies with meaningful Quick Ratio only.
CBIO' s Quick Ratio Range Over the Past 10 Years
Min: 0.89  Med: 6.07 Max: 60.98
Current: 50.15
0.89
60.98
Days Sales Outstanding 11.63
CBIO's Days Sales Outstanding is ranked higher than
89% of the 656 Companies
in the Global Biotechnology industry.

( Industry Median: 64.11 vs. CBIO: 11.63 )
Ranked among companies with meaningful Days Sales Outstanding only.
CBIO' s Days Sales Outstanding Range Over the Past 10 Years
Min: 8.61  Med: 23.75 Max: 102.62
Current: 11.63
8.61
102.62

Buy Back

vs
industry
vs
history
5-Year Yield-on-Cost % 229.00
CBIO's 5-Year Yield-on-Cost % is ranked higher than
100% of the 308 Companies
in the Global Biotechnology industry.

( Industry Median: 1.56 vs. CBIO: 229.00 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
CBIO' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 35.1  Med: 140.92 Max: 241.45
Current: 229
35.1
241.45
3-Year Average Share Buyback Ratio -145.10
CBIO's 3-Year Average Share Buyback Ratio is ranked lower than
78% of the 768 Companies
in the Global Biotechnology industry.

( Industry Median: -13.20 vs. CBIO: -145.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
CBIO' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -464.6  Med: -12.5 Max: 0
Current: -145.1
-464.6
0

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 2.00
CBIO's Price-to-Net-Cash is ranked higher than
59% of the 568 Companies
in the Global Biotechnology industry.

( Industry Median: 8.85 vs. CBIO: 2.00 )
Ranked among companies with meaningful Price-to-Net-Cash only.
CBIO' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 0.87  Med: 2.18 Max: 17.44
Current: 2
0.87
17.44
Price-to-Net-Current-Asset-Value 1.97
CBIO's Price-to-Net-Current-Asset-Value is ranked higher than
66% of the 695 Companies
in the Global Biotechnology industry.

( Industry Median: 7.88 vs. CBIO: 1.97 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
CBIO' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 0.5  Med: 1.77 Max: 15.94
Current: 1.97
0.5
15.94
Price-to-Tangible-Book 1.97
CBIO's Price-to-Tangible-Book is ranked higher than
60% of the 874 Companies
in the Global Biotechnology industry.

( Industry Median: 5.88 vs. CBIO: 1.97 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
CBIO' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.49  Med: 1.4 Max: 11.54
Current: 1.97
0.49
11.54
Price-to-Median-PS-Value 14.50
CBIO's Price-to-Median-PS-Value is ranked lower than
96% of the 614 Companies
in the Global Biotechnology industry.

( Industry Median: 1.00 vs. CBIO: 14.50 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
CBIO' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.08  Med: 0.85 Max: 27.95
Current: 14.5
0.08
27.95
Earnings Yield (Greenblatt) % -17.52
CBIO's Earnings Yield (Greenblatt) % is ranked lower than
52% of the 1060 Companies
in the Global Biotechnology industry.

( Industry Median: -6.86 vs. CBIO: -17.52 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
CBIO' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -1305.1  Med: -12.8 Max: 7639.6
Current: -17.52
-1305.1
7639.6

More Statistics

Revenue (TTM) (Mil) $0.75
EPS (TTM) $ -5.39
Beta2.56
Volatility135.02%
52-Week Range $3.11 - 37.00
Shares Outstanding (Mil)11.94

Piotroski F-Score Details

Piotroski F-Score: 44
Positive ROAN
Positive CFROAN
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyY
Less Shares Outstanding yoyN
Higher Gross Margin yoyN
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}